Summary Estimation of tumour proliferation may allow the design of individualised radiotherapy schedules to optimise response. This prospective study correlates the tumour proliferation rate of cervical carcinoma with response to conventional radiotherapy. The potential tumour cell doubling rate (Tpot) was estimated following flash labelling of the tumours in vivo using the DNA precursor, bromodeoxyuridine (BrdUrd); samples were analysed by flow cytometry. Tumour ploidy, DNA index and mitotic count were also assessed as was histological grade and type. Multiple biopsies from each tumour were obtained from 121 women. The median Tpot was 4.0 days, median S-phase duration 12.8 h and median adjusted labelling index 9.8%. Higher BrdUrd labelling was seen in patients who developed pelvic tumour recurrence following radiotherapy. This was the only biological/histological parameter with univariate and multivariate significance in relation to locoregional recurrence (P = 0.006 and P = 0.034 respectively). This study represents the first assessment of Tpot in relation to long-term response of cervical tumours treated by radiotherapy treatment. The association of high BrdUrd labelling and poor pelvic disease-free survival indicates the need for further research into the potential of radiotherapy schedule alteration to reflect tumour proliferation. The predictive value may be enhanced by combination with other biological parameters.
Local recurrence can be a significant problem following radiotherapy for carcinoma of the cervix. This is particularly true of more advanced stage tumours. Local recurrence is seen in only 10% of stage lb patients, but in stage IIIb disease, pelvic recurrence rate is greater than 40% (Davidson et al., 1989) . Both clinical and laboratory data suggest repopulation during treatment may be an important factor leading to failure to achieve local control of the tumour (Trott and Kummermehr, 1985) . In order to reduce repopulation during treatment, radiotherapy can be given over a shorter time period, often two or three times a day using a fraction size of less than 2 Gy. It is unclear whether all patients would benefit from accelerated radiotherapy schedules. Initial results from a randomised study of radiotherapy schedule alteration in head and neck cancer (Saunders et al., 1991) suggest that local control is improved in patients receiving accelerated hyperfractionated radiotherapy in rapidly proliferating tumours only (Begg et al., 1992) . Measurement of tumour proliferation rate may, therefore, help to select patients most likely to benefit from new or accelerated schedules for radiotherapy.
There is inconclusive evidence regarding the relationship between measured tumour proliferation parameters and prognosis in cervical carcinoma (Dixon et al., 1977; Strang et al., 1987a,b; Naus and Zimmerman, 1991; Cole et al., 1992; Zanetta et al., 1992; Tsang et al., 1995) . The techniques used in the measurement of proliferation in these studies included the assessment of growth fraction using Ki67 immunocytochemistry, the flow cytometric estimation of S-phase fraction and the tritiated thymidine labelling method. Only one study used in vivo bromodeoxyuridine labelling (Tsang et al., 1995 (Begg et al., 1985 (Begg et al., , 1988 Wilson et al., 1988) . It also has the advantage of providing an in vivo assessment of proliferation. This paper reports the results from the assessment of cervical carcinoma proliferation rate through the labelling of tumours in vivo using bromodeoxyuridine (BrdUrd) (Bolger et al., 1993) . In brief, a nuclear suspension was produced by pepsin disaggregation of a 50 mg portion of tumour. The incorporated BrdUrd was revealed through the partial denaturation of the DNA using hydrochloric acid. (Begg et al., 1985) .
Calculation of S-phase (Ti) duration
The derivation of T, assumes that at the time of labelling the average DNA content of labelled cells lies midway between the G, and the G2 peaks. It also assumes that the progression of cells through S-phase is constant. The average cell progression rate through S-phase can be calculated provided the mean DNA content of labelled undivided cells and the time interval between labelling and biopsy is known. All flash-labelled S-phase cells are expected to reach G2 by a time equal to T., thus from the progression rate a value for T, can be derived.
No calculation of T, or adjusted LI could be performed for aneuploid tumours if there was gross overlap of the Sphase labelled cells.
Calculated cell kinetic parameters
The potential doubling time was derived from the equation:
adjusted LI L is a correction factor for the non-linear distribution of cells through the cell cycle (Steel, 1977) . We have used a constant value of 0.8 in our calculations.
Radiotherapy schedules Early lesions (stage I and II<5 cm) received two intracavity insertions using the selectron after loading machine (16 patients). The average A point dose was 36 Gy (from both insertions) at a dose rate of 1.8 Gy h-'. This was followed by 3 weeks' (14 fractions) treatment with 4MeV X-rays to parallel opposed diamond-shaped fields with the selectrontreated area covered with a compensation wedge. Stepwise multivariate logistic regression analysis was performed on the parameters listed in Table II . The model selected defined only tumour size and adjusted BrdUrd LI as having independent prognostic significance with regard to pelvic disease-free survival following radiotherapy (Table III) . All other parameters had P-value>0.17 and were therefore rejected.
Actuarial pelvic disease-free survival was compared for above/below median adjusted BrdUrd LI (Figure 1 ). This provides consistent evidence that patients with elevated (above median) labelling have significantly greater chance of developing a local recurrence (log-rank, P=0.002). In the analysis of histological type, 11/121 were defined as adenocarcinoma. Tumours were divided into three groups according to the mitotic count per high-powered field (< 1, 1 -5, > 5) tumour ploidy was defined as diploid or aneuploid. Radiotherapy is a local treatment and the most valid assessment is locoregional control. The determination of pelvic disease-free survival, therefore, allows the most discriminating assessment of the relationship between tumour cell kinetics and radiotherapy response. This analysis based on a median survival of 34 months should provide an accurate prediction of local recurrence rate; in 78% of women destined to develop pelvic recurrence a diagnosis will be made within 24 months of treatment (Van Nagell et al., 1979) .
This study indicates that the principal difference in tumour proliferation parameters where local control was not achieved, is an elevated proliferating fraction (as indicated by the increase in BrdUrd labelling index). This is a consistent finding in uni-and multivariate analysis. These findings are as predicted by tumour clonogenic repopulation studies. Interestingly, these results also indicate that T, is longer in radiotherapy-resistant tumours. There is little published data on the evaluation of Ts and treatment response; however, no previous study has defined this difference. The absolute difference between the median values of Ts for radiotherapy-sensitive and resistant tumours is small and the biological significance is uncertain.
Prolongation of T, may result from the fact that a larger proportion of the cell population is recruited into the cell cycle with a resultant lengthening of cell cycle time. One implication of this finding, however, is that the estimation of Tpot is less predictive of local tumour control because the lengthening of T, has an opposite effect to the elevation of BrdUrd LI in the calculation of Tpot. If labelling index alone is confirmed to provide greatest prognostic information, the clinical application of these measurements would be facilitated because it is the simplest parameter to measure and does not require a labelling/biopsy delay.
A recently published study relating Tpot to radiotherapy response in cervical carcinoma reports similar findings. The inability of this study to determine statistically significant differences may relate to the inadequate follow-up duration (minimum 7 and mean 16 months) and the small numbers included in the study (46) (Tsang et al., 1995) . This analysis defines BrdUrd labelling index as the most predictive parameter, in keeping with our results.
In common with other studies, there is no convincing evidence that histological type, grade, mitotic index, DNA ploidy or DNA index are of any predictive value. Analysis of other histological and clinical features was undertaken to exclude any association of cell kinetics with these parameters. The definition of BrdUrd LI, in a multivariate analysis, as the second best predictor of local tumour recurrence indicates the significant role this parameter plays in relation to local recurrence. It is noteworthy that tumour size has a greater predictive value than stage. This illustrates the limitations of the current staging system and clearly demonstrates the value of the proposed incorporation of tumour size in the FIGO staging of lb disease (Creasman, 1995) . The need to record tumour size in other stages remains unaddressed.
The radiotherapy schedules used in this centre are relatively short compared with the conventional schedule used for head and neck tumours as reported in the EORTC cooperative trial (Begg et al., 1992) . The duration lies at the point, defined by Begg (1994) , below which rapidly growing tumours are unlikely to gain advantage from further acceleration. The findings of this study question this proposed level and, more significantly, indicate that protraction of treatment schedules beyond 5 weeks may provide inadequate treatment for tumours with a high labelling index.
In conclusion, these results indicate that measurement of pretreatment tumour cell kinetics may predict failure to achieve local tumour control. The BrdUrd labelling index has the greatest predictive value of all parameters measured. This data identifies the need to examine current radiotherapy (Levine et al., 1994) , have been shown to be predictive of radiotherapy response. In combination with these parameters, individualisation of treatment may become feasible to optimise treatment response.
